ストックスクリーナーアプリを入手
2.00
9.09%
-0.20
アフターアワーズ：
2.03
0.03
+1.50%
前日終値:
$2.20
開ける：
$2.29
24時間の取引高:
46,025
Relative Volume:
0.63
時価総額：
$27.44M
収益：
-
当期純損益:
$-11.61M
株価収益率:
-1.5449
EPS:
-1.2946
ネットキャッシュフロー:
$-11.82M
1週間 パフォーマンス:
-13.79%
1か月 パフォーマンス:
-27.27%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.98
$2.29
1週間の範囲:
$1.98
$2.40
52週間の値動き範囲:
$1.98
$4.965
Grace Therapeutics Inc Stock (GRCE) Company Profile
GRCE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
2.00 | 27.44M | 0 | -11.61M | -11.82M | -1.2946 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-09-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-07-06 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2020-01-13 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2019-08-29 | 開始されました | B. Riley FBR | Buy |
| 2019-07-18 | 開始されました | Oppenheimer | Outperform |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Grace Therapeutics Inc (GRCE) 最新ニュース
Acasti Pharma stock plunges to 52-week low at $2.02 By Investing.com - Investing.com UK
Aneurysmal Subarachnoid Hemorrhage Market to Reach New Heights - openPR.com
Aneurysmal Subarachnoid Hemorrhage Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Acasti Pharma Inc., BIT Pharma, Aaron Cook, Haaglanden Medical Centre - Barchart.com
February’s phase III wins include Qyuns’ ankylosing spondylitis data - BioWorld MedTech
Grace Therapeutics secures up to $30 million financing - MSN
ASUS Introduces Ascent GX10 AI Supercomputer Powered by NVIDIA GB10 Grace Blackwell Superchip - Yahoo Finance
Cadence Accelerates AI-Driven Engineering Design and Science with NVIDIA Grace Blackwell - Yahoo Finance
Subarachnoid Hemorrhage Treatment Market Size in the 7MM - openPR
Acasti Pharma stock hits 52-week low at $2.12 amid challenges - Investing.com Australia
Acasti Pharma stock hits 52-week low at $2.12 amid challenges By Investing.com - Investing.com South Africa
Tesla’s fall from grace may have no equal, says JPMorgan: ‘We struggle to think of anything analogous’ - Yahoo Finance
The Inner Circle acknowledges, Grace Merrell Slezak as a Pinnacle Professional Member Inner Circle of Excellence - Yahoo Finance
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem - Yahoo Finance
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
Grace Therapeutics Reports Q3 Progress and Financial Results - TipRanks
Grace Therapeutics Files Form S-3 for Flexible Securities Offering - TipRanks
Grace Therapeutics to offer up to 8.8 mln shares by selling stockholders, SEC Filing shows - Marketscreener.com
Moderna, Inc. - Britannica
CORTCorcept Therapeutics Inc Latest Stock News & Market Updates - StockTitan
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
CORCEPT THERAPEUTICS INC SEC 10-K Report - TradingView
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Grace Therapeutics' Novel aSAH Treatment Impress Investors at Major Healthcare Conference? - StockTitan
Grace Therapeutics reports positive Phase 3 trial results for GTx-104 - MSN
GRCE: STRIVE-ON Results Reported - MSN
Corcept Therapeutics stock soars to all-time high of $62.34 - MSN
Grace Therapeutics’ (GRCE) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright reiterates buy on Grace Therapeutics stock By Investing.com - Investing.com Australia
H.C. Wainwright reiterates buy on Grace Therapeutics stock - Investing.com India
Promising Potential of Grace Therapeutics’ GTX-104 Drives Buy Rating - TipRanks
Grace Therapeutics On Track For NDA Submission Of GTx-104 For Aneurysmal Subarachnoid Hemorrhage - Nasdaq
GRACE THERAPEUTICS Earnings Results: $GRCE Reports Quarterly Earnings - Nasdaq
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Reports Positive Phase 3 STRIVE-ON Trial Results for GTx-104 and Secures $30 Million in Financing; NDA Submission Expected by Mid-2025 - Nasdaq
Grace Therapeutics Inc. (GRCE) reports earnings - Quartz
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results - TradingView
Grace Reports Clinical Trial Victory and Major Cash Infusion in Latest Earnings - StockTitan
Grace Therapeutics, Inc. SEC 10-Q Report - TradingView
Grace Therapeutics secures up to $30 million financing By Investing.com - Investing.com Nigeria
Grace Therapeutics secures $15m for GTx-104 pre-commercial development - MSN
Grace therapeutics announces private placement financing of $30 million - MSN
Grace Therapeutics Inc (GRCE) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):